[{"orgOrder":0,"company":"Pluri","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Emiplacel","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pluri \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pluri \/ Inapplicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Emiplacel","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pluri \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pluri \/ Inapplicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Emiplacel","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pluri \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pluri \/ Inapplicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Emiplacel","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pluri \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pluri \/ Inapplicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Emiplacel","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pluri \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pluri \/ Inapplicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Emiplacel","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pluri \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pluri \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stero Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Stero Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Stero Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Stero Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"K S Kim International","sponsor":"MGC Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"ArtemiC","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"K S Kim International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"K S Kim International \/ MGC Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"K S Kim International \/ MGC Pharmaceuticals"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Israel Innovation Authority","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Funding","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Israel Innovation Authority","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Israel Innovation Authority"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Israel Innovation Authority","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Funding","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Israel Innovation Authority","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Israel Innovation Authority"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"Allocetra","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Enlivex Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"BiomX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"BX211","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical","sponsorNew":"BiomX \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BiomX \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : BX211 is being evaluated in mid-stage clinical trial studies. It is a phage for the Diabetic Foot Osteomyelitis associated with S. aureus.

                          Product Name : BX211

                          Product Type : Microorganism

                          Upfront Cash : Inapplicable

                          March 31, 2025

                          Lead Product(s) : BX211

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Allocetra™ is an off-the-shelf cell therapy that reprograms macrophages and has shown positive results in sepsis associated with pneumonia and other infections.

                          Product Name : Allocetra-OTS

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          November 04, 2024

                          Lead Product(s) : Allocetra-OTS

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : RHB-107, a proprietary, first-in-class, once-daily orally administered investigational antiviral, is currently undergoing mid-stage clinical trials for treating Covid-19.

                          Product Name : RHB-107

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 24, 2024

                          Lead Product(s) : Upamostat

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Allocetra-OTS is a cell-based therapy of non-HLA-matched allogeneic peripheral blood mononuclear cells, for sepsis associated with pneumonia, biliary, urinary tract, or peritoneal infections.

                          Product Name : Allocetra-OTS

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          February 21, 2024

                          Lead Product(s) : Allocetra-OTS

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells. It is under phase 2 clinical trials for sepsis associated with pneumonia, biliary, urinary tract, or peritoneal infections.

                          Product Name : Allocetra-OTS

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          December 20, 2023

                          Lead Product(s) : Allocetra-OTS

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Allocetra is being developed as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Drug has the potential to provide a novel immunotherapeutic action for life-threatening indications such as solid canc...

                          Product Name : Allocetra-OTS

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          July 31, 2023

                          Lead Product(s) : Allocetra-OTS

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The finding aims to support RedHill to focus on the development of RHB-107 (upamostat), a potent inhibitor of serine proteases. It is being evaluated in the treatment of early outpatientand post-exposure prophylaxis for Severe Acute Respiratory Syndrome ...

                          Product Name : RHB-107

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          April 12, 2023

                          Lead Product(s) : Upamostat

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Henry M. Jackson Foundation

                          Deal Size : $4.8 million

                          Deal Type : Funding

                          blank

                          08

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Allocetra-OTS is being developed as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Drug has the potential to provide a novel immunotherapeutic action for life-threatening indications such as solid ...

                          Product Name : Allocetra-OTS

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          April 01, 2023

                          Lead Product(s) : Allocetra-OTS

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Enlivex is developing Allocetra™ as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, and many others reprogram macrophages out of their homeostatic state.

                          Product Name : Allocetra-OTS

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          August 29, 2022

                          Lead Product(s) : Allocetra-OTS

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Allocetra™ is being developed as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, and many others reprogram macrophages out of their homeostatic state.

                          Product Name : Allocetra-OTS

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          August 24, 2022

                          Lead Product(s) : Allocetra-OTS

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank